Novartis Pharma AG: Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favora ...

Pixel Agents Creates a Pixel Office View for Your AI Coding Agents

Pixel Agents adds a pixel office view in VS Code; six character styles show coding, searching, or idle states, useful for ...
Heart

Timeless therapeutics: cardiac indications for vitamin K antagonists in clinical practice

Anticoagulation is a critical component in the treatment of cardiovascular diseases. Large randomised controlled trials have ...
The Manila Times

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with ...